Finerenone, chronic obstructive pulmonary disease, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS-HF trial.

There was a nominally significant interaction between COPD status and the effect of finerenone on improvement in NYHA class from baseline to 12 months, such that finerenone appeared to improve NYHA class in patients with COPD, but not in those without COPD ( p interaction = 0.048) ( Table 3 ).

also in 7,732 other papers